19-May-2003
NEL HOME, Newsletter
AIM & SCOPE
BOARD OF EDITORS
INSTRUCTIONS
CONTENTS Vol.24 Nos.1/2 Feb-Apr 2003
VOL.22, 2001
VOL.21, 2000
VOL.20, 1999
VOL.19, 1998
VOL.18, 1997
HUMAN ETHOLOGY
PREVIEW coming
PRESS ROOM
CONTACT
SUBSCRIBE order

NEUROENDOCRINOLOGY LETTERS
including Psychoneuroimmunology, Neuropsychopharmacology,
Reproductive Medicine, Chronobiology
and Human Ethology, ISSN 0172–780X

NEL Vol.24 No.1/2, Feb-Apr 2003

REVIEW ARTICLE

Perspectives of somatostatin analogs

2003; 24:2127
pii: NEL241203R01
PMID:
12743527

[Read pdf 143kb]

Buy PDF article
Check Out

 

Perspectives of new potential therapeutic applications of somatostatin analogs*

Marek Pawlikowski & Gabriela Melen-Mucha

Department of Experimental Endocrinology and Hormone Diagnostics, Institute of Endocrinology, Medical University of Lodz, POLAND.

Submitted: November 20, 2002 Accepted: December 16, 2002

Key words:
somatostatin analogs, clinical applications

Abstract

At the present time only two long-acting somatostatin (SS) analogs, octreotide and lanreotide, are commonly used in the routine therapy. Both analogs have a high affinity mainly to a somatostatin receptor subtype 2 (SSTR2). The established indications for SS analogs treatment include acromegaly, neuroendocrine tumors of the pancreas and gastrointestinal tract, and some gastro-enterologic diseases (pancreatitis, gastrointestinal bleedings, refractory diarrheas, pancreatic and intestinal fistulas). The recent investigations allow to predict the enlargement of therapeutic applications of SS analogs. It concerns pituitary tumors other than somatotropinoma, tumors of other endocrine glands like thyroid and adrenal gland, as well as some non-endocrine tumors. The progress depends on the introduction of new SS analogs with high affinity for SS receptor subtypes other than SSTR2, because some tumors present the high expression of SSTR1 (e.g. prostatic cancers) or SSTR5 (e.g. colonic cancers). Great hopes are connected with the coupling of SS analogs with the radioactive isotopes or non-radioactive cytotoxic agents to destruct the neoplastic cells highly expressing the specific subtypes of SS receptors.
The pre- or postoperative in vivo imaging of SS receptors by means of the receptor scintigraphy, as well as the post-operative identification of SS receptor subtypes in the excised tumor tissues using immunohistochemistry, should play an important role in the prediction of the effects of SS analog treatment.
Beside oncology, new therapeutic applications of SS analogs could be presumed among others in ophthalmology; it concerns the treatment of progressive Graves-Basedow ophtalmopathy, diabetic retinopathy, glaucoma and corneal diseases connected with corneal vascularization.

 

__________________________________________________________
Copyright  Neuroendocrinology Letters 2003
Society of Integrated Sciences
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief.
The latest statistics from the www.nel.edu